Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors
- PMID: 27720783
- PMCID: PMC5241176
- DOI: 10.1016/j.juro.2016.09.113
Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors
Abstract
Purpose: Fibrosis accounts for approximately 50% of histological findings at post-chemotherapy retroperitoneal lymph node dissection, and is associated with reported relapse rates of 10% to 15%. We characterized patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection and identified predictors of adverse outcomes in this group.
Materials and methods: We reviewed the medical records of men who underwent post-chemotherapy retroperitoneal lymph node dissection between 1989 and 2013 with histological findings of necrosis/fibrosis. With few exceptions post-chemotherapy retroperitoneal lymph node dissection after 1999 was performed with a bilateral template. Clinical, pathological and treatment related data were reported. Cox regression models were built to identify predictors of disease recurrence.
Results: The study cohort included 598 men with a median age of 32 years (IQR 25-38). Most cases (397 of 547, 73%) were classified as IGCCCG good risk, with no significant differences in risk classification before and after 1999 (p=0.55). Median followup was 7.3 years (IQR 3.2-12.3). The 5-year recurrence-free and overall survival rates were 94% and 96%, respectively. Overall 36 patients had disease recurrence, most of which was distant or outside the retroperitoneal lymph node dissection template. Procedures performed after 1999 and the presence of embryonal cell carcinoma on primary histology were associated with improved recurrence-free survival on multivariate analysis (p <0.01).
Conclusions: Disease recurrence in patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection is an uncommon yet significant event, which is less likely to occur in patients treated after 1999 and in those with embryonal carcinoma on primary histology.
Keywords: fibrosis; germ cell and embryonal; lymph node excision; neoplasms.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
and Disclosure Statement All authors have nothing to disclose.
Figures
Comment in
-
Editorial Comment.J Urol. 2017 Feb;197(2):396. doi: 10.1016/j.juro.2016.09.129. Epub 2016 Nov 9. J Urol. 2017. PMID: 27836453 No abstract available.
-
Editorial Comment.J Urol. 2017 Feb;197(2):396-397. doi: 10.1016/j.juro.2016.09.130. Epub 2016 Nov 9. J Urol. 2017. PMID: 27836457 No abstract available.
Similar articles
-
Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival.J Urol. 2014 Jun;191(6):1777-82. doi: 10.1016/j.juro.2014.01.010. Epub 2014 Feb 8. J Urol. 2014. PMID: 24518787
-
The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.J Urol. 2015 Feb;193(2):507-12. doi: 10.1016/j.juro.2014.09.090. Epub 2014 Sep 22. J Urol. 2015. PMID: 25254937
-
Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.Int J Urol. 2015 Jul;22(7):663-8. doi: 10.1111/iju.12760. Epub 2015 Apr 6. Int J Urol. 2015. PMID: 25847721
-
Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors.Urol Clin North Am. 2015 Aug;42(3):343-6. doi: 10.1016/j.ucl.2015.04.008. Epub 2015 Jun 6. Urol Clin North Am. 2015. PMID: 26216821 Review.
-
Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.J Urol. 2021 Feb;205(2):370-382. doi: 10.1097/JU.0000000000001364. Epub 2020 Sep 11. J Urol. 2021. PMID: 32915080
Cited by
-
Recent developments in the management of germ cell tumors.Curr Opin Oncol. 2017 May;29(3):172-178. doi: 10.1097/CCO.0000000000000361. Curr Opin Oncol. 2017. PMID: 28151756 Free PMC article.
-
Matrix biophysical cues direct mesenchymal stromal cell functions in immunity.Acta Biomater. 2021 Oct 1;133:126-138. doi: 10.1016/j.actbio.2021.07.075. Epub 2021 Aug 5. Acta Biomater. 2021. PMID: 34365041 Free PMC article. Review.
-
Irreversible electroporation ablation of end-stage metastatic retroperitoneal lesions: Report on three cases and literature review.Exp Ther Med. 2019 Sep;18(3):2243-2249. doi: 10.3892/etm.2019.7780. Epub 2019 Jul 17. Exp Ther Med. 2019. PMID: 31410175 Free PMC article.
-
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.Ann Oncol. 2025 Jun;36(6):693-703. doi: 10.1016/j.annonc.2025.03.002. Epub 2025 Mar 10. Ann Oncol. 2025. PMID: 40073938
-
Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures.Cancer Imaging. 2024 Nov 18;24(1):156. doi: 10.1186/s40644-024-00794-5. Cancer Imaging. 2024. PMID: 39558421 Free PMC article. Review.
References
-
- Stevenson SM, Lowrance WT. Epidemiology and Diagnosis of Testis Cancer. Urol Clin North Am. 2015;42:269. - PubMed
-
- Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol. 2004;22:225. - PubMed
-
- Donohue JP, Einhorn LH, Williams SD. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol. 1980;123:876. - PubMed
-
- Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;13:1177. - PubMed
-
- Spiess PE, Brown GA, Pisters LL, et al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006;107:1503. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical